Intellia Therapeutics Inc (NASDAQ:NTLA) rose 11.9% on Wednesday . The company traded as high as $21.82 and last traded at $21.51. Approximately 1,086,700 shares were traded during trading, an increase of 20% from the average daily volume of 904,700 shares. The stock had previously closed at $19.22.

NTLA has been the topic of a number of recent research reports. ValuEngine raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Wedbush reaffirmed an “ourperform” rating and set a $25.00 price objective (down from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. Jefferies Group reaffirmed a “buy” rating and set a $36.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, October 3rd. Zacks Investment Research raised Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Finally, Leerink Swann lifted their price objective on Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a report on Tuesday, October 31st. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $30.17.

The company has a market capitalization of $932.22 and a P/E ratio of -14.21.

Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Tuesday, October 31st. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative net margin of 215.92% and a negative return on equity of 28.01%. The company had revenue of $7.30 million during the quarter, compared to analysts’ expectations of $5.83 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. Intellia Therapeutics’s quarterly revenue was up 49.0% compared to the same quarter last year. equities research analysts predict that Intellia Therapeutics Inc will post -1.68 EPS for the current year.

In related news, CEO Nessan Bermingham sold 336,783 shares of the business’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $20.78, for a total value of $6,998,350.74. Following the completion of the transaction, the chief executive officer now owns 696,000 shares in the company, valued at approximately $14,462,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Institutes For Biomed Novartis sold 1,523,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $18.30, for a total transaction of $27,870,900.00. The disclosure for this sale can be found here. Insiders sold 1,971,283 shares of company stock valued at $37,137,161 in the last quarter. 12.80% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of NTLA. Schwab Charles Investment Management Inc. raised its position in Intellia Therapeutics by 6.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 26,903 shares of the company’s stock worth $380,000 after purchasing an additional 1,539 shares during the last quarter. Bank of Montreal Can raised its position in Intellia Therapeutics by 1,031.7% in the 2nd quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after purchasing an additional 7,222 shares during the last quarter. Rhumbline Advisers bought a new position in Intellia Therapeutics in the 2nd quarter worth approximately $275,000. State of Wisconsin Investment Board bought a new position in Intellia Therapeutics in the 2nd quarter worth approximately $160,000. Finally, SG Americas Securities LLC bought a new position in Intellia Therapeutics in the 2nd quarter worth approximately $101,000. Hedge funds and other institutional investors own 48.95% of the company’s stock.

WARNING: “Intellia Therapeutics (NTLA) Stock Price Up 11.9%” was first published by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/intellia-therapeutics-ntla-stock-price-up-11-9/1795172.html.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.